6.2 Hepatic Enzymes: Transaminases (AST, ALT), ALP, GGT & De Ritis Ratio

6.2 Hepatic Enzymes: Transaminases (AST, ALT), ALP, GGT & De Ritis Ratio

[!NOTE] Diagnostic Classification of Hepatic Enzymes: The clinical chemistry laboratory evaluates liver function and pathology through two distinct enzyme categories: (1) Hepatocellular Injury (Cytotoxic / Leakage) Enzymes, primarily the aminotransferases AST and ALT, which leak into systemic circulation upon cell membrane breakdown or necrosis; and (2) Cholestatic (Hepatobiliary / Obstructive) Enzymes, including ALP, GGT, and 5'-Nucleotidase (5'-NT), which are localized to biliary canalicular membranes and undergo induced de novo synthesis and detergent-mediated solubilization during biliary stasis.

---

The Aminotransferases (Transaminases)

The aminotransferases catalyze the reversible interconversion of amino acids and $\alpha$-keto acids via the transfer of an $\alpha$-amino group. They play a foundational role in intermediary protein metabolism and gluconeogenesis, linking amino acid catabolism with the Krebs citric acid cycle.

+-----------------------------------------------------------------------------------------+
|                   Comparison of Aspartate and Alanine Aminotransferase                  |
+-----------------------------------------------------------------------------------------+
| Feature           Aspartate Aminotransferase (AST)      Alanine Aminotransferase (ALT)  |
+-----------------------------------------------------------------------------------------+
| Historical Name   Serum Glutamic-Oxaloacetic            Serum Glutamic-Pyruvic          |
|                   Transaminase (SGOT)                   Transaminase (SGPT)             |
|                                                                                         |
| Substrates        L-Aspartate + α-Ketoglutarate         L-Alanine + α-Ketoglutarate     |
| Products          Oxaloacetate + L-Glutamate            Pyruvate + L-Glutamate          |
|                                                                                         |
| Required Coenzyme Pyridoxal-5'-phosphate (P-5'-P / B6)  Pyridoxal-5'-phosphate (P-5'-P) |
|                                                                                         |
| Subcellular Site  Cytosolic (cAST, ~20%) and            Cytosolic strictly (>95%)       |
|                   Mitochondrial (mAST, ~80%)                                            |
|                                                                                         |
| Primary Tissue    Liver, Cardiac Muscle, Skeletal       Predominantly Liver Parenchyma  |
| Distribution      Muscle, Kidneys, Brain, RBCs          (Highly Liver Specific)         |
|                                                                                         |
| Circulating T1/2  ~17 hours (cytosolic AST)             ~47 hours (significantly longer)|
|                                                                                         |
| Coupled Assay     Karmen Method coupled to Malate       Wroblewski-LaDue Method coupled |
| Reaction          Dehydrogenase (MDH); NADH at 340 nm   to Lactate Dehydrogenase (LDH)  |
|                                                                                         |
| Hemolysis Effect  EXTREME FALSE ELEVATION (40-80x RBC)  MINIMAL EFFECT (4-7x in RBC)    |
+-----------------------------------------------------------------------------------------+

Aspartate Aminotransferase (AST / SGOT)

• Enzymatic Reaction: Catalyzes the transfer of an amino group from aspartate to $\alpha$-ketoglutarate, producing oxaloacetate and glutamate: $\text{L-Aspartate} + \alpha\text{-Ketoglutarate} \xrightleftharpoons{\text{AST, P-5'-P}} \text{Oxaloacetate} + \text{L-Glutamate}$
• Tissue Distribution: Distributed in broad organ systems: Heart > Liver > Skeletal Muscle > Kidneys > Pancreas > Erythrocytes. Because of this wide distribution, elevated AST is not specific for hepatic disease and can indicate myocardial infarction, rhabdomyolysis, muscular dystrophy, or strenuous physical exertion.
• Intracellular Localization: Exists as two distinct genetic isoenzymes: cytosolic AST ($cAST$) and mitochondrial AST ($mAST$). In healthy hepatocytes, approximately 80% of total AST activity resides within the mitochondria. Mild hepatocellular injury releases primarily cytosolic AST; severe cellular necrosis, ischemia, or alcohol-induced mitochondrial disruption triggers marked release of mitochondrial AST into serum.
• The Karmen Coupled Reference Method:
  1. AST transamination generates oxaloacetate.
  2. Oxaloacetate is immediately reduced to L-malate by exogenous indicator enzyme Malate Dehydrogenase (MDH), coupled to the simultaneous oxidation of $\text{NADH}$ to $\text{NAD}^+$: $\text{Oxaloacetate} + \text{NADH} + \text{H}^+ \xrightarrow{\text{MDH}} \text{L-Malate} + \text{NAD}^+$
  3. The reaction rate is measured continuously at 340 nm by the decrease in absorbance per minute ($\Delta A/\text{min}$).
  4. Coenzyme Supplementation: Reagent formulations standardized by the IFCC incorporate exogenous Pyridoxal-5'-Phosphate (P-5'-P). In patients with Vitamin $B_6$ deficiency (chronic alcoholics, hemodialysis patients), circulating transaminases exist partly as catalytically inactive apoenzymes. Exogenous P-5'-P reactivates the apoenzyme, avoiding false underestimation.
• Hemolysis Pitfall: Human erythrocytes contain 40 to 80 times more AST than normal serum. Even trace in vitro hemolysis causes profound false elevation of serum AST. Specimens showing visible pink-to-red discoloration must be rejected.

Alanine Aminotransferase (ALT / SGPT)

• Enzymatic Reaction: Catalyzes the transfer of an amino group from alanine to $\alpha$-ketoglutarate, producing pyruvate and glutamate: $\text{L-Alanine} + \alpha\text{-Ketoglutarate} \xrightleftharpoons{\text{ALT, P-5'-P}} \text{Pyruvate} + \text{L-Glutamate}$
• Tissue Distribution: Highly concentrated in liver parenchymal cells. Found only in trace concentrations in cardiac muscle, skeletal muscle, and kidneys. Therefore, ALT is markedly more liver-specific than AST.
• Intracellular Localization: ALT is almost exclusively localized within the hepatocyte cytoplasm. It is readily released upon even minor alterations in hepatocellular membrane permeability.
• The Wroblewski-LaDue Coupled Reference Method:
  1. ALT transamination generates pyruvate.
  2. Pyruvate is coupled to indicator enzyme Lactate Dehydrogenase (LDH), which converts pyruvate to L-lactate with concurrent oxidation of $\text{NADH}$ to $\text{NAD}^+$: $\text{Pyruvate} + \text{NADH} + \text{H}^+ \xrightarrow{\text{LDH}} \text{L-Lactate} + \text{NAD}^+$
  3. Monitored continuously via the rate of decrease in absorbance at 340 nm.
• Hemolysis Sensitivity: Human erythrocytes contain only 4 to 7 times the ALT activity of serum. Consequently, mild hemolysis does not artifactually distort ALT to the extreme degree seen with AST, though recollection is still recommended for grossly hemolyzed samples.

---

The De Ritis Ratio (AST / ALT) & Clinical Interpretation

In 1957, Fernando De Ritis demonstrated that the numerical ratio of serum AST to serum ALT ($[\text{AST}] / [\text{ALT}]$) provides powerful differential diagnostic information regarding the etiology, severity, and chronicity of liver injury.

+-----------------------------------------------------------------------------------------+
|                    Clinical Patterns of the De Ritis Ratio (AST/ALT)                    |
+-----------------------------------------------------------------------------------------+
| Clinical Condition               AST & ALT Levels       De Ritis Ratio   Key Mechanism  |
+-----------------------------------------------------------------------------------------+
| Acute Viral Hepatitis           Marked elevation       < 1.0            Massive cyto-  |
| (HAV, HBV, HCV)                  (10x - 100x+ ULN;      (often 0.5-0.7)  solic ALT flood|
|                                  ALT > AST)                              Longer ALT T1/2|
|                                                                                         |
| Toxic / Ischemic Necrosis        Extreme elevation      < 1.0            Total cellular |
| (Acetaminophen overdose,         (often > 3,000 to      (initially)      lysis; massive |
| "Shock Liver" / Hypoperfusion)   > 10,000 U/L)                           ALT release    |
|                                                                                         |
| Alcoholic Liver Disease          Modest elevation       ≥ 2.0            Mitochondrial  |
| (Alcoholic Hepatitis,            (rarely > 300-500 U/L; (often > 3.0 in  AST release;   |
| Cirrhosis)                       AST > ALT)             cirrhosis)       B6 deficiency  |
|                                                                          blunts ALT     |
|                                                                                         |
| Chronic Hepatitis C / NAFLD      Mild-to-moderate       < 1.0            Low-grade cyto-|
| (Early non-fibrotic stages)      (< 2x - 5x ULN)                         solic leakage  |
|                                                                                         |
| Advanced Hepatic Cirrhosis       Mild elevation or      > 1.0            Fibrotic loss; |
| (End-stage architectural remodeling) near normal        (Inverted ratio) impaired AST   |
|                                                                          sinusoid clear.|
+-----------------------------------------------------------------------------------------+

Pathophysiological Rationale of Diagnostic Patterns

1. Acute Viral Hepatitis & Ischemic / Toxic Necrosis ($[\text{AST}] / [\text{ALT}] < 1.0$):
   • In acute viral hepatitis (Hepatitis A, B, or C), diffuse parenchymal inflammation leads to massive leakage of soluble cytosolic enzymes. Hepatocytes contain immense quantities of cytoplasmic ALT.
   • ALT has a significantly longer plasma half-life (~47 hours) compared to cytosolic AST (~17 hours). As a result, ALT accumulates to higher concentrations and persists longer in the circulation.
   • Transaminases frequently exceed 1,000 to 5,000 U/L (20 to 100+ times upper limit of normal [ULN]). ALT exceeds AST, yielding a characteristic ratio $< 1.0$ (typically 0.5 to 0.7).
   • In toxic acetaminophen (Tylenol) overdose and acute ischemic hepatitis ("shock liver"), transaminases surge to astronomical levels (frequently > 10,000 U/L), accompanied by acute coagulopathy (prolonged Prothrombin Time / INR) and early De Ritis $< 1.0$.
2. Alcoholic Liver Disease ($[\text{AST}] / [\text{ALT}] \ge 2.0$):
   • In alcoholic hepatitis and alcoholic cirrhosis, transaminase levels are typically only moderately elevated (rarely exceeding 300 to 500 U/L). An AST exceeding 500 U/L in an alcoholic patient should prompt immediate investigation for coexisting acetaminophen toxicity or ischemic injury.
   • Despite modest absolute numbers, AST is substantially higher than ALT, yielding a De Ritis ratio $\ge 2.0$ (and often $> 3.0$ in active alcoholic cirrhosis).
   • Two Underlying Biochemical Mechanisms:
     1. Mitochondrial Toxicity: Ethanol and its primary toxic metabolite, acetaldehyde, exert direct organelle toxicity upon hepatocyte mitochondria, inducing severe inner-membrane swelling and mitochondrial lysis. This triggers preferential release of mitochondrial AST (mAST), flooding the serum with AST.
     2. Pyridoxal-5'-Phosphate (Vitamin $B_6$) Depletion: Chronic alcoholism causes severe dietary malnutrition and ethanol-mediated destruction of hepatic P-5'-P. The apoenzyme of ALT has a substantially weaker binding affinity for P-5'-P than apo-AST. Consequently, hepatic ALT synthesis and activity are crippled far more severely than AST.
3. Progression of Chronic Hepatitis to Cirrhosis (The Ratio Inversion):
   • In early chronic hepatitis C and non-alcoholic fatty liver disease (NAFLD), ALT typically exceeds AST ($[\text{AST}]/[\text{ALT}] < 1.0$).
   • As progressive hepatic fibrosis advances toward end-stage cirrhosis, the ratio gradually rises and inverts to $> 1.0$.
   • This inversion is driven by: (1) loss of functional hepatocyte mass; (2) reduced hepatic sinusoidal clearance of AST by damaged sinusoidal endothelial cells; and (3) mitochondrial injury in surviving, stressed hepatocytes.

---

Alkaline Phosphatase (ALP)

Alkaline Phosphatase comprises a family of zinc metalloenzymes with a serine residue at the active site that non-specifically hydrolyze monophosphate esters at an alkaline pH (9.8 to 10.5), liberating free inorganic phosphate:

$\text{Organic Phosphate Ester} + \text{H}_2\text{O} \xrightarrow[\text{pH } 9.8\text{--}10.5]{\text{ALP, Mg}^{2+}, \text{Zn}^{2+}} \text{Alcohol} + \text{Inorganic Phosphate (P}_i)$

Tissue Distribution and Physiology

ALP is attached to cell membranes via a glycosylphosphatidylinositol (GPI) anchor at sites of intense membrane transport activity:

• Hepatobiliary Canalicular Membrane: Located on the microvillar surface of bile canaliculi and ductular epithelial cells.
• Bone Osteoblasts: Synthesized by osteoblasts to hydrolyze inorganic pyrophosphate (a mineralization inhibitor), facilitating hydroxyapatite crystallization during osteogenesis.
• Placental Trophoblasts: Present in syncytiotrophoblasts during pregnancy.
• Intestinal Mucosa: Brush-border epithelial cells of the small intestine (especially in individuals with ABO blood groups O or B who are secretors).
• Renal Proximal Tubules: Excreted into urine; does not contribute significantly to serum activity.

Analytical Methodology: Bowers-McComb Reference Method

• The internationally accepted reference method utilizes $p$-nitrophenylphosphate (pNPP) as a colorless substrate in 2-amino-2-methyl-1-propanol (AMP) buffer at pH 10.4: $p\text{-Nitrophenylphosphate (colorless)} + \text{H}_2\text{O} \xrightarrow[\text{AMP, pH 10.4}]{\text{ALP, Mg}^{2+}, \text{Zn}^{2+}} p\text{-Nitrophenol (yellow)} + \text{Phosphate}$
• The indicator product, $p$-nitrophenol, exhibits intense yellow absorbance measured spectrophotometrically at 405 nm.
• The assay requires $\text{Mg}^{2+}$ as a catalytic activator and $\text{Zn}^{2+}$ as an integral structural cation. Inhibited by EDTA, oxalate, and citrate.

Physiological vs Pathological Elevations

• Physiological Elevations:
  • Pediatric and Adolescent Skeletal Growth: Growing children exhibit serum ALP levels 2 to 3 times adult reference intervals due to rapid osteoblastic bone elongation.
  • Normal Pregnancy: Placental ALP appears in maternal serum around the 16th to 20th week of gestation, rising steadily to peak during the third trimester (up to 2-fold adult ULN) before normalizing within 3 to 6 weeks postpartum.
• Pathological Elevations:
  • Hepatobiliary Disease (Cholestasis): Biliary obstruction (choledocholithiasis, pancreatic head adenocarcinoma, primary sclerosing cholangitis, biliary atresia) causes 3- to 10-fold elevations of ALP. Bile accumulation induces de novo ALP synthesis by canalicular epithelial cells, while the detergent action of retained bile acids solubilizes the membrane-anchored ALP into sinusoidal blood.
  • Bone Disorders (Osteoblastic Activity):
    • Paget Disease of Bone (Osteitis Deformans): Characterized by uncontrolled, frantic osteoblastic remodeling; produces the highest serum ALP levels seen in clinical medicine (often 10- to 25-fold ULN).
    • Osteomalacia and Rickets: Vitamin D deficiency causing impaired mineralization and compensatory osteoblast proliferation.
    • Osteosarcoma and Osteoblastic Metastases: Common in prostate adenocarcinoma and breast carcinoma metastatic to bone.
    • Healing Bone Fractures: Transient moderate elevations.
    • Note: Uncomplicated osteoporosis causes osteoclastic resorption without osteoblastic surge; serum ALP is typically normal.

ALP Isoenzyme Differentiation Techniques

When an isolated elevation of ALP is detected, the clinical laboratory employs specific analytical fractionation techniques to pinpoint the tissue of origin:

+-----------------------------------------------------------------------------------------+
|                        ALP Isoenzyme Differentiation Techniques                         |
+-----------------------------------------------------------------------------------------+
| Isoenzyme   Heat Stability Test       Agarose Electrophoresis  Chemical Inhibitor       |
|             (56°C for 10 min)         Mobility (Anode +)       Sensitivity              |
+-----------------------------------------------------------------------------------------+
| Placental   EXTREMELY STABLE          Intermediate             Inhibited by             |
|             (Resists 65°C for 30 min)                          L-Phenylalanine          |
|                                                                                         |
| Intestinal  MODERATELY STABLE         Cathodal / Slowest       Inhibited by             |
|             (~50-60% remains)         (near origin)            L-Phenylalanine          |
|                                                                                         |
| Liver       MODERATELY STABLE         Fastest / Anodal         Inhibited by             |
|             (~20% activity remains)   (Migrates farthest)      Levamisole               |
|                                                                                         |
| Bone        EXTREMELY HEAT-LABILE     Intermediate-Fast        Inhibited by             |
|             (< 10-20% remains;        (Behind liver)           Levamisole               |
|             "Bone Burns!")                                                              |
+-----------------------------------------------------------------------------------------+

1. Heat Inactivation Test (The 56°C / 10-Minute Incubation):
   • Patient serum is heated in a precision water bath at 56°C for exactly 10 minutes, rapidly cooled on ice, and assayed alongside an unheated aliquot.
   • Placental ALP: Retains 100% activity at 56°C and resists denaturation even at 65°C for 30 minutes.
   • Liver ALP: Moderately stable; approximately 20% to 30% residual activity remains.
   • Bone ALP: Extremely heat-labile; denatures rapidly with < 10% to 20% activity remaining. Standard laboratory mnemonic: "Bone Burns!"
2. Electrophoretic Fractionation:
   • On agarose gel or cellulose acetate at alkaline pH (8.6), isoenzymes migrate toward the anode (+) in the following sequence: $\text{Anode (+)} \longleftarrow \text{Liver} > \text{Bone} > \text{Placental} > \text{Intestinal} \longleftarrow \text{Cathode (-)}$
   • In cholestatic liver disease, an additional fast-migrating high-molecular-weight band called $\alpha_1$-liver (macromolecular ALP) appears.
3. Neuraminidase Treatment:
   • Neuraminidase selectively hydrolyzes terminal sialic acid residues. Because liver ALP contains more terminal sialic acid residues than bone ALP, neuraminidase incubation retards liver ALP migration on electrophoresis, permitting clean resolution between bone and liver bands.
4. Carcinoplacental Isoenzymes (Ectopic Tumor Markers):
   • Regan Isoenzyme: An ectopic placental-like ALP synthesized by malignant tumors (bronchogenic carcinoma, ovarian adenocarcinoma). Identical to placental ALP (heat-stable at 65°C, inhibited by L-phenylalanine).
   • Nagao Isoenzyme: Variant carcinoplacental ALP observed in testicular germ cell tumors and pancreatic carcinoma; inhibited by both L-phenylalanine and L-leucine.

---

Gamma-Glutamyltransferase (GGT) & 5'-Nucleotidase (5'-NT)

Gamma-Glutamyltransferase (GGT)

• Biochemical Role: A microsomal and plasma-membrane peptidase that transfers $\gamma$-glutamyl groups from peptides (such as glutathione) to other amino acids or small peptides, playing a key role in cellular glutathione recycling and amino acid absorption.
• Tissue Distribution: Highly active in renal proximal tubules (highest tissue concentration, but clears into urine), biliary canalicular epithelium, hepatocytes, pancreas, and prostate.
• CRITICAL DIAGNOSTIC FACT: GGT IS COMPLETELY ABSENT IN BONE TISSUE AND THE PLACENTA.
• Clinical Diagnostic Role:
  1. Resolving Elevated ALP Etiology:
     • Elevated ALP + Elevated GGT: Confirms a hepatobiliary etiology (cholestasis, biliary duct obstruction, hepatic infiltration).
     • Elevated ALP + Normal GGT: Confirms a bone disorder (Paget disease, rickets, osteosarcoma, healing fracture) or normal physiological state (adolescent growth spurt, pregnancy).
  2. Surveillance Marker for Occult Alcohol Intake: GGT is a highly sensitive clinical marker for chronic alcohol consumption. Alcohol ingestion induces the synthesis of hepatic microsomal enzymes. Serum GGT rises before visible liver histopathology occurs, normalizing after 2 to 3 weeks of strict abstinence.
  3. Drug-Induced Microsomal Enzyme Induction: Anticonvulsant medications (Phenytoin, Carbamazepine, Phenobarbital) induce hepatic microsomal GGT synthesis, producing moderate-to-marked elevations of serum GGT in the absence of true liver injury.

5'-Nucleotidase (5'-NT)

• Biochemical Role: A canalicular phosphatase that specifically hydrolyzes nucleoside-5'-monophosphates (such as AMP) into nucleosides (adenosine) and inorganic phosphate.
• Clinical Diagnostic Role: Like GGT, 5'-NT is elevated in hepatobiliary disease but is normal in bone disease. It serves as an independent confirmatory test when GGT results are confounded by alcohol intake or enzyme-inducing anticonvulsants.

---

Comprehensive Diagnostic Enzyme Matrix

+-----------------------------------------------------------------------------------------+
|                    Comprehensive Clinical Diagnostic Enzyme Matrix                      |
+-----------------------------------------------------------------------------------------+
| Clinical Condition          AST       ALT       ALP       GGT       5'-NT   CK / LD     |
+-----------------------------------------------------------------------------------------+
| Acute Viral Hepatitis      ↑↑↑       ↑↑↑↑      Normal/↑  ↑-↑↑      ↑       Normal      |
|                            (10-50x)  (20-100x) (< 3x)    (Modest)  (Modest)             |
|                                                                                         |
| Toxic Acetaminophen Lysis  ↑↑↑↑      ↑↑↑↑      Normal/↑  ↑-↑↑      ↑       Normal      |
|                            (>100x)   (>100x)   (< 2x)    (Modest)  (Modest)             |
|                                                                                         |
| Alcoholic Hepatitis        ↑↑ (AST>ALT) ↑      Normal/↑  ↑↑↑       ↑       Normal      |
| (De Ritis ≥ 2.0)           (<500U/L) (<200U/L) (< 2x)    (Induction)                    |
|                                                                                         |
| Biliary Obstruction        ↑-↑↑      ↑-↑↑      ↑↑↑↑      ↑↑↑↑      ↑↑↑↑    Normal      |
| (Choledocholithiasis, etc) (1-3x)    (1-3x)    (3-10x+)  (5-15x+)  (3-10x)              |
|                                                                                         |
| Paget Disease of Bone      Normal    Normal    ↑↑↑↑      NORMAL    NORMAL  Normal      |
| (Osteitis Deformans)                           (10-25x+) (No Bone) (No Bone)            |
|                                                                                         |
| Skeletal Muscle Trauma     ↑↑↑       Normal/↑  Normal    NORMAL    NORMAL  ↑↑↑↑ (CK)   |
| (Rhabdomyolysis, Crush)    (Muscle)  (Minimal)           (No Bone)         ↑↑ (LD-5)   |
|                                                                                         |
| Adolescent Growth Spurt    Normal    Normal    ↑↑ (2-3x) NORMAL    NORMAL  Normal      |
| (Physiological)                                (Bone)    (No Bone)                      |
|                                                                                         |
| Normal 3rd Trimester       Normal    Normal    ↑↑ (2x)   NORMAL    NORMAL  Normal      |
| Pregnancy (Physiological)                      (Placenta)(No Bone)                      |
+-----------------------------------------------------------------------------------------+